Topical Ocular TRPV1 Antagonist SAF312 (Libvatrep) Demonstrates Safety, Low Systemic Exposure, and No Anesthetic Effect in Healthy Participants.

Kalliopi Stasi, Qusai Alshare,Monish Jain,Michael Wald,Yifang Li

Translational vision science & technology（2022）

引用 5|浏览2

暂无评分

摘要

This work bridges the gap between basic research and clinical care by providing FIH data of SAF312, supporting the further investigation as a potential treatment for ocular surface pain.

查看译文

关键词

libvatrep,anesthetic effect,low systemic exposure

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要